yttrium Y 90 glass microspheres
Sponsors
Allan Tsung, University of Pittsburgh, Goshen Health System, Northwestern University, City of Hope Medical Center
Conditions
Adult Primary Hepatocellular CarcinomaAdvanced Adult Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerBCLC Stage B Hepatocellular CarcinomaBCLC Stage C Hepatocellular CarcinomaCiliary Body and Choroid Melanoma, Medium/Large SizeCiliary Body and Choroid Melanoma, Small SizeExtraocular Extension Melanoma
Early Phase 1
Radioembolization and Ipilimumab in Treating Patients With Uveal Melanoma With Liver Metastases
TerminatedNCT01730157
Start: 2012-12-31End: 2016-02-29Updated: 2016-03-10
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot be Removed by Surgery
CompletedNCT02072356
Start: 2010-10-11End: 2021-06-15Updated: 2022-09-30
Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection
TerminatedNCT03812562
Start: 2019-02-07End: 2023-10-19Updated: 2024-02-21
Phase 1
Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
CompletedNCT00858429
Start: 2009-04-01End: 2014-07-08Updated: 2019-09-09
Nivolumab and Yttrium Y 90 Glass Microspheres in Treating Patients With Advanced Liver Cancer
CompletedNCT02837029
Start: 2016-07-31End: 2020-11-01Updated: 2022-01-25
Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial
RecruitingNCT06432036
Start: 2024-12-26End: 2027-06-01Target: 25Updated: 2026-03-06
Phase 2
Radiolabeled Glass Beads (TheraSphere®) in Treating Patients With Primary Liver Cancer That Cannot Be Removed by Surgery
WithdrawnNCT00039078
Start: 2000-08-31End: 2000-08-31Updated: 2017-06-26
Internal Radiation Therapy With Y-90 Microspheres, External Radiation Therapy With Tomotherapy, and Fluorouracil in Treating Patients With Newly Diagnosed or Recurrent Pancreatic Cancer and Liver Metastases That Cannot Be Removed By Surgery
NCT00436267
Start: 2006-11-30Target: 20Updated: 2013-12-19
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery
CompletedNCT00956930
Start: 2009-08-31End: 2016-07-15Updated: 2022-11-21
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
CompletedNCT01900002
Start: 2013-09-13End: 2020-12-10Updated: 2021-12-30
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma
WithdrawnNCT05327738
Start: 2022-12-10End: 2027-12-04Updated: 2022-12-14
Phase 3
Unknown Phase
Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
CompletedNCT00530010
Start: 2004-12-31End: 2022-03-08Target: 500Updated: 2022-08-12
Radiolabeled Glass Beads in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
CompletedNCT00532740
Start: 2004-12-31End: 2022-03-16Target: 2000Updated: 2022-08-12
Yttrium Y 90 Radiolabeled Glass Beads in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
NCT00589030
Start: 2007-04-30End: 2014-09-30Updated: 2017-02-15
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma
CompletedNCT01176604
Start: 2010-08-04End: 2021-04-09Updated: 2022-10-14
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)
Active, not recruitingNCT03896646
Start: 2019-10-10End: 2026-09-30Updated: 2025-11-21